Loading clinical trials...
Loading clinical trials...
Sintilimab, Bevacizumab Plus Y-90 Selective Internal Radiation Therapy for Patients With Unresectable Intermediate-advanced Hepatocellular Carcinoma: a Prospective, Single-center, Single Arm Trial
Conditions
Interventions
Sin-Bev-SIRT
Locations
1
China
the Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Start Date
May 1, 2024
Primary Completion Date
April 30, 2027
Completion Date
April 30, 2027
Last Updated
May 7, 2024
NCT06707233
NCT05911633
NCT06187961
NCT06561399
NCT04224636
NCT05901194
Lead Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions